OpenAI’s structure continues to baffle investors hoping for a pure-play stake in the AI boom. Despite a 2025 restructuring that formalized its for-profit public-benefit division, the company remains private, with no plans for an IPO in 2026. Ordinary investors cannot buy OpenAI shares on a stock exchange this year.

That doesn’t mean you’re entirely locked out. The closest public proxy is Microsoft, which has pumped over $13 billion into OpenAI since 2019. Through its Azure cloud platform and revenue-sharing agreements, Microsoft absorbs a hefty slice of OpenAI’s commercial upside. Yet indirect exposure comes with caveats—and a host of risks and contradictions.

This article dissects the three main paths to invest in OpenAI in 2026: buying Microsoft stock, navigating private secondary markets, and waiting for a potential IPO. We’ll also examine the pitfalls, from corporate governance chaos to valuation turbulence.

Microsoft Stock: The Blunt Instrument

For most people, Microsoft (MSFT) is the only liquid, regulated vehicle to ride the ChatGPT wave. Microsoft’s partnership with OpenAI runs deep: exclusive cloud provider, technology integration into Copilot, Bing, and Office, and a reported 75% share of OpenAI’s profits until its investment is recouped, then a 49% stake moving forward. When you buy MSFT, you’re buying a diversified tech giant, but one whose AI ambitions pivot heavily on OpenAI’s success.

Why the Proxy Works

Microsoft’s quarterly earnings increasingly highlight AI-driven revenue. In its FY2025 Q2 report (released January 2025), the company noted that Azure OpenAI Service revenue more than doubled year-over-year, driven by enterprise adoption of GPT-4o models. CEO Satya Nadella declared that “AI transformation is now driving results at scale.” Every time an enterprise buys Azure credits for OpenAI APIs, or a consumer subscribes to Copilot Pro, Microsoft records revenue that traces directly back to OpenAI’s technology.

This coupling is not 1:1. Microsoft’s $2.2 trillion-plus market cap also captures Windows, LinkedIn, GitHub, and a sprawling enterprise software empire. A 10% move in OpenAI’s hypothetical valuation might shift MSFT by a fraction of a percent. Yet over the past twelve months, MSFT’s stock performance has correlated roughly 0.6 with AI-themed indexes like the BITA AI Leaders Index, according to data from Morningstar. That’s a meaningful, if imprecise, link.

The Cap-Table Hedge

Another nuance: Microsoft’s investment is structured as convertible notes and equity in OpenAI Global, LLC, the capped-profit subsidiary. This design means Microsoft’s returns are capped—at a 100x multiplier on its initial investment, per reporting from The Wall Street Journal. If OpenAI’s valuation skyrockets into the trillions, Microsoft won’t capture the full upside. Still, for ordinary investors, that cap only matters in a scenario far beyond current models, and MSFT remains the simplest vessel.

Private Secondary Markets: The High-Risk Backdoor

Sophisticated and accredited investors can sometimes buy OpenAI shares on private secondary platforms like Forge Global, EquityZen, or Nasdaq Private Market. These marketplaces allow early employees and existing backers to sell their stakes before an IPO. In early 2026, spot trades for OpenAI stock have been reported at prices implying a valuation between $120 billion and $160 billion, according to secondary data tracked by Caplight.

How It Works

Transactions happen off-exchange, with settlement periods measured in days rather than seconds. Buyers must be accredited—earning $200,000+ annually or holding $1 million in net worth—and often face minimums of $25,000 to $100,000. The shares are typically common stock with no voting rights, no board representation, and heavy transfer restrictions.

Liquidity is sparse. A trade might take weeks to execute, and the supply of sellers can dry up if insiders think an IPO is near. Pricing is opaque; brokers negotiate between bids and asks, often creating spreads of 5-10%. For example, a February 2026 transaction tracked by one secondary broker involved 1,500 shares at a per-share price of $185, equivalent to a $148 billion valuation, but with a 7% spread that effectively cost the buyer $198 per share.

OpenAI’s corporate governance doesn’t make it easy. The company’s operating agreement still grants its nonprofit board veto power over the for-profit arm, a structure that survived the 2025 reorganization. Secondary purchasers have no contractual rights under that agreement; they’re essentially betting the board won’t do something that destroys equity value. Moreover, some secondary trades have been contested by OpenAI’s management, who argue unapproved transfers violate the right of first refusal clauses in early employee stock options. Court filings in Delaware have shown at least three unresolved lawsuits over such transfers since mid-2025.

Direct Investment: An IPO Still Out of Reach

OpenAI’s leadership has been coy about public listing. CEO Sam Altman told the World Economic Forum in Davos in January 2026 that “going public is not the priority right now; our structure still isn’t right for public markets.” CFO Sarah Friar echoed that sentiment, pointing to the need for predictable cash flows—something a loss-making AI lab still burning billions on training runs can’t easily demonstrate.

The Profitability Hurdle

OpenAI’s leaked internal projections, reported by The Information in November 2025, foresee revenue of $11.6 billion in 2026 but a net loss of $2.3 billion, driven by compute costs. That’s a dramatic improvement over 2024’s $3.7 billion loss, but hardly a classic IPO candidate. Public investors demand a path to earnings; OpenAI’s path remains speculative, hinging on enterprise deals like its $11.9 billion multi-year cloud commitment with Microsoft announced in December 2025.

The Governance Puzzle

Even after the 2025 restructuring into a Delaware Public Benefit Corporation (PBC), the nonprofit parent retains special voting stock that can override the for-profit arm’s decisions in “safety and mission-critical matters.” This arrangement unsettles public-market investors accustomed to shareholder primacy. Proxy advisory firm ISS recommended against an OpenAI listing in a June 2025 report, citing “insufficient separation between commercial and altruistic objectives.” Until OpenAI either unwinds that control or convinces the SEC it’s workable, an S-1 filing remains unlikely.

The Risks Nobody Wants to Talk About

Investing in OpenAI—even indirectly—carries risks that standard tech stocks don’t.

Regulatory Threats

Antitrust regulators are circling. The Federal Trade Commission’s ongoing inquiry into the Microsoft-OpenAI relationship, opened in December 2024, could force structural changes. FTC Chair Lina Khan stated in a February 2026 congressional hearing that “the concentration of AI model development and cloud infrastructure raises serious competition concerns.” A forced divestiture or breakup would crater the proxy value of MSFT’s stake and destabilize OpenAI’s valuation.

In Europe, the EU AI Act’s transparency mandates for general-purpose AI systems could impose compliance costs that eat into margins. OpenAI has already allocated $450 million in 2026 for “responsible AI infrastructure,” according to a company blog post, directly citing regulatory requirements.

Technical and Competitive Risk

OpenAI’s moat is under assault. Google’s Gemini 2.0, Anthropic’s Claude 3.5, and open-source models like Meta’s Llama 4 are closing the performance gap. In November 2025, the Stanford HELM benchmark showed Claude 3.5 Opus edging out GPT-5 on reasoning tasks for the first time. If open-source models reach parity, OpenAI’s pricing power—and hence Microsoft’s margins—will shrink.

Additionally, training costs are ballooning. GPT-5’s final training run in Q3 2025 consumed an estimated $750 million in GPU time, per SemiAnalysis. Future frontier models may require $5-10 billion each, straining a balance sheet that relies on repeated fundraises.

The Altman Factor

Sam Altman’s continued leadership is both an asset and a liability. His November 2023 ouster and return demonstrated the board’s volatility. Though the 2025 restructure overhauled the board, Altman’s control remains less absolute than a typical founder-CEO. Key talent has departed: Chief Scientist Ilya Sutskever left in May 2024 to start his own venture, and VP of Engineering David Luan followed in October 2024. These departures add uncertainty to the pipeline.

What Should an Investor Do in 2026?

If you believe in the AI thesis and want exposure, start with MSFT. It’s liquid, transparent, and pays a dividend (currently 0.75% yield). But recognize that you’re getting a blended bet, not a pure AI play. For every dollar MSFT earns from OpenAI workloads, it earns multiple dollars from Xbox Game Pass subscriptions and LinkedIn ads.

For accredited investors, secondary purchases offer a direct stake but with hair-raising illiquidity and risk. Average holding periods for pre-IPO stock on secondary platforms extended to 3.2 years in 2025, per Equidate, and there’s no guarantee of a liquidity event. Only go this route if you can afford a total loss of that capital.

Avoid overpaying for hype. Secondary premiums often bake in unrealistic growth. If OpenAI’s 2026 revenue comes in below the $11.6 billion target, those $185 share prices could halve overnight.

Looking Ahead

An OpenAI IPO will happen eventually—perhaps in 2028 or 2029, once the loss-making phase subsides and governance stabilizes. Until then, Microsoft remains the de facto ETF for OpenAI’s commercial progress. Savvy investors will monitor Microsoft’s quarterly Azure AI growth figures (disclosed in earnings calls) and OpenAI’s secondary market pricing for clues. And they’ll stay vigilant to regulatory tailwinds that could reshape the landscape overnight. In tech investing, patience is rarely as well-rewarded as when dealing with a company that’s rewriting the rules—and yet still refuses to sell you a ticket.